Evidence map›Paper›PMID 30310596›Full record

ArticleChemical science2018

Silyl-mediated photoredox-catalyzed Giese reaction: addition of non-activated alkyl bromides.

Abdellatif ElMarrouni, Casey B Ritts, Jaume Balsells

Abstract read
In one paragraph

Article in Chemical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Monofluoromethyl Radical Mediated Halogen-Atom Transfer.Journal of the American Chemical Society · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sulfonium Salts as Acceptors in Electron Donor-Acceptor Complexes.Angewandte Chemie (International ed. in English) · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Photoinduced Halogen-Atom Transfer byJournal of the American Chemical Society · 2023
    Article
  15. PeptideACS central science · 2022
    Article
  16. C(spChemical science · 2022
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abdellatif ElMarrouniDepartment of Discovery Chemistry , MRL , Merck & Co., Inc. , 770 Sumneytown Pike , West Point , Pennsylvania 19486 , USA . Email: abdellatif.el.marrouni@merck.com.ORCID 0000-0001-5408-0374
Casey B RittsDepartment of Process Research & Development , MRL , Merck & Co., Inc. , 770 Sumneytown Pike , West Point , Pennsylvania 19486 , USA . Email: jaume.balsells@merck.com.ORCID 0000-0002-1734-3128
Jaume BalsellsDepartment of Process Research & Development , MRL , Merck & Co., Inc. , 770 Sumneytown Pike , West Point , Pennsylvania 19486 , USA . Email: jaume.balsells@merck.com.ORCID 0000-0002-2000-4178

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of photoredox catalysis has enabled the discovery of mild and efficient conditions for the generation of a variety of radical reaction platforms. Herein is disclosed the development of a conjugate addition reaction of non-activated alkyl bromides to Michael acceptors under visible-light photoredox catalysis. Optimization of the reaction was achieved using high-throughput experimentation (HTE) tools to enable the identification of mild, general and practical reaction conditions. A diverse set of alkyl bromides was successfully added to cyclic or acyclic α,β-unsaturated esters and amides. The features of this transformation allowed also access to a key intermediate of Vorinostat®, an HDAC inhibitor used to fight cancer and HIV.

Identifiers

PMID30310596
PMCPMC6115631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.